Company: KROS
Filing Date: 2025-05-06
Form Type: 10-Q
Source: 0001664710-25-000046
Chunk: 164

Company: Keros Therapeutics, Inc.
Filing Date: 2025-05-06
Form: 10-Q
Item: Item 8
Chunk 164
---
 two twelve-month purchase periods.Under the ESPP, there is an annual increase on January 1 of each year from January 1, 2021 continuing through January 1, 2030, by the lesser of (i) 1.0% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, (ii) 455,852 shares or (iii) or a lesser number of shares as may be determined by the Board. On January 1, 2025, the Company increased the number of shares available for future grant under the ESPP by 405,547 shares. If purchase rights granted under the ESPP terminate without having been exercised, the shares of our common stock not purchased under such purchase rights will again become available for issuance under the ESPP.As of March 31, 2025, no shares of common stock were purchased under the ESPP. As of March 31, 2025, there was an aggregate of 1,653,408 shares reserved for future issuance under the ESPP.Stock-Based Compensation Expense Total stock-based compensation expense recorded for employees, directors and non-employees during the three months ended March 31, 2025 and 2024 was as follows (in thousands):THREE MONTHS ENDED MARCH 31,20252024Research and development$5,265 $3,902 General and administrative3,598 4,168 Total stock-based compensation expense$8,863 $8,070 

8. INCOME (LOSS) PER SHARE

Basic and diluted income (loss) per share of common stock are calculated as follows (in thousands, except share and per share data):THREE MONTHS ENDED MARCH 31,20252024Numerator:Net income (loss) attributable to common stockholders - basic and diluted$148,451 $(43,114)Denominator:Weighted-average shares of common stock outstanding - basic40,559,355 35,685,422 Effect of potentially dilutive stock options460,730 — Effect of potentially dilutive employee stock purchase plan shares914 — Effect of potentially dilutive restricted stock units326 — Total potentially dilutive securities461,970 — Weighted-average shares of common stock outstanding used to compute diluted net loss41,021,325 35,685,422 Net income (loss) per share of common stockBasic$3.66 $(1.